X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (23233) 23233
Publication (2093) 2093
Book Review (106) 106
Book Chapter (57) 57
Newsletter (41) 41
Conference Proceeding (28) 28
Dissertation (23) 23
Book / eBook (3) 3
Magazine Article (3) 3
Data Set (2) 2
Newspaper Article (2) 2
Paper (2) 2
Reference (2) 2
Trade Publication Article (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (16304) 16304
cisplatin (11815) 11815
index medicus (10908) 10908
animals (8484) 8484
oncology (8264) 8264
cisplatin - pharmacology (7765) 7765
female (7756) 7756
male (6218) 6218
cancer (6146) 6146
chemotherapy (6079) 6079
cell line, tumor (5763) 5763
antineoplastic agents - pharmacology (5702) 5702
apoptosis (5232) 5232
mice (4229) 4229
apoptosis - drug effects (3636) 3636
middle aged (3508) 3508
cisplatin - administration & dosage (3122) 3122
expression (3098) 3098
pharmacology & pharmacy (3086) 3086
biochemistry & molecular biology (3010) 3010
aged (2858) 2858
adult (2681) 2681
rats (2428) 2428
cisplatin - therapeutic use (2213) 2213
drug resistance, neoplasm (2191) 2191
antineoplastic combined chemotherapy protocols - therapeutic use (2172) 2172
cell biology (2112) 2112
cell survival - drug effects (2030) 2030
antineoplastic agents - therapeutic use (1979) 1979
cisplatin - toxicity (1949) 1949
tumor cells, cultured (1938) 1938
dose-response relationship, drug (1892) 1892
research (1891) 1891
proteins (1866) 1866
analysis (1864) 1864
tumors (1815) 1815
drug resistance (1807) 1807
resistance (1749) 1749
cell proliferation - drug effects (1722) 1722
carcinoma (1653) 1653
lung neoplasms - drug therapy (1630) 1630
care and treatment (1586) 1586
antineoplastic agents (1553) 1553
gene expression (1549) 1549
prognosis (1495) 1495
dna damage (1470) 1470
ovarian neoplasms - drug therapy (1466) 1466
ovarian cancer (1447) 1447
in-vitro (1419) 1419
cells (1406) 1406
cisplatin - adverse effects (1388) 1388
activation (1381) 1381
treatment outcome (1373) 1373
antimitotic agents (1369) 1369
inhibition (1348) 1348
cytotoxicity (1345) 1345
cancer therapies (1333) 1333
article (1324) 1324
cisplatin - metabolism (1322) 1322
mice, nude (1318) 1318
oxidative stress (1314) 1314
health aspects (1300) 1300
dna (1290) 1290
toxicity (1285) 1285
drug synergism (1271) 1271
ovarian neoplasms - metabolism (1229) 1229
survival (1223) 1223
time factors (1203) 1203
lung cancer (1190) 1190
lung neoplasms - pathology (1171) 1171
lung neoplasms - metabolism (1166) 1166
gene expression regulation, neoplastic (1154) 1154
immunohistochemistry (1153) 1153
platinum (1146) 1146
therapy (1142) 1142
ovarian neoplasms - pathology (1126) 1126
blotting, western (1107) 1107
antineoplastic agents - toxicity (1106) 1106
signal transduction (1092) 1092
toxicology (1091) 1091
metastasis (1090) 1090
dna repair (1080) 1080
cell line (1045) 1045
phosphorylation (1042) 1042
research article (1041) 1041
drug resistance, neoplasm - genetics (1039) 1039
xenograft model antitumor assays (1038) 1038
neoplasms - drug therapy (1036) 1036
genetic aspects (1030) 1030
antineoplastic agents - administration & dosage (1027) 1027
medicine, research & experimental (1015) 1015
cell cycle (1013) 1013
kidney - drug effects (1004) 1004
breast-cancer (996) 996
carcinoma, non-small-cell lung - drug therapy (976) 976
signal transduction - drug effects (975) 975
gene expression regulation, neoplastic - drug effects (964) 964
antineoplastic agents - adverse effects (962) 962
nephrotoxicity (962) 962
transfection (948) 948
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (22836) 22836
Japanese (413) 413
Chinese (343) 343
Russian (68) 68
French (58) 58
German (31) 31
Polish (15) 15
Spanish (14) 14
Italian (9) 9
Korean (8) 8
Ukrainian (5) 5
Hungarian (4) 4
Portuguese (3) 3
Dutch (2) 2
Amharic (1) 1
Bulgarian (1) 1
Danish (1) 1
Slovak (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


PLoS ONE, ISSN 1932-6203, 2010, Volume 5, Issue 11, p. e14062
Background: The cancer stem cell theory hypothesizes that cancers are perpetuated by cancer stem cells (CSC) or tumor initiating cells (TIC) possessing... 
COLON-CANCER | POPULATION | MARKER | MULTIDISCIPLINARY SCIENCES | GROWTH | HYALURONAN | PLURIPOTENCY | FLOW-CYTOMETRY | IDENTIFICATION | CD133(+) | TUMORS | Immunohistochemistry | Humans | Lung Neoplasms - metabolism | Middle Aged | Glycoproteins - metabolism | Peptides - genetics | Immunoblotting | Lung Neoplasms - pathology | Male | Transplantation, Heterologous | Gene Expression Profiling | Antigens, CD - genetics | Antigens, CD - metabolism | Neoplasms, Experimental - pathology | Octamer Transcription Factor-3 - genetics | Flow Cytometry | Peptides - metabolism | Neoplastic Stem Cells - metabolism | Hyaluronan Receptors - metabolism | Neoplasms, Experimental - genetics | Neoplastic Stem Cells - pathology | Female | Nuclear Proteins - genetics | Repressor Proteins - metabolism | Carcinoma, Non-Small-Cell Lung - pathology | Glycoproteins - genetics | Lung Neoplasms - genetics | Proto-Oncogene Proteins - metabolism | Carcinoma, Non-Small-Cell Lung - genetics | Carcinoma, Non-Small-Cell Lung - metabolism | Repressor Proteins - genetics | Nuclear Proteins - metabolism | Proto-Oncogene Proteins - genetics | Reverse Transcriptase Polymerase Chain Reaction | AC133 Antigen | Hyaluronan Receptors - genetics | Animals | Polycomb Repressive Complex 1 | Mice, Nude | Octamer Transcription Factor-3 - metabolism | Cell Line, Tumor | Aged | Mice | Neoplasms, Experimental - metabolism | Squamous cell carcinoma | Lung cancer, Non-small cell | Analysis | Stem cells | Flow cytometry | Biotechnology | Laboratories | Heart surgery | Oct-4 protein | Lung cancer | Colorectal cancer | Stem cell transplantation | Proteins | Allografts | Epidermal growth factor | CD44 antigen | Xenografts | Cell cycle | CD34 antigen | Subpopulations | Cell survival | Tumor cells | Non-small cell lung carcinoma | Tumor cell lines | Cisplatin | Studies | Polymerase chain reaction | Pathology | Cytometry | Properties (attributes) | Medical prognosis | Cell lines | Biomarkers | In vivo methods and tests | Pluripotency | Tumors | Apoptosis | Cancer
Journal Article
PLoS ONE, ISSN 1932-6203, 01/2013, Volume 8, Issue 1, p. e54193
Introduction: Inherent and acquired cisplatin resistance reduces the effectiveness of this agent in the management of non-small cell lung cancer (NSCLC).... 
OVEREXPRESSION | ARREST | IN-VITRO | DNA | PHARMACOLOGY | MULTIDISCIPLINARY SCIENCES | SENSITIVITY | AGENTS | COPPER | OVARIAN-CANCER | IDENTIFICATION | Proto-Oncogene Proteins c-met - metabolism | DNA Adducts - drug effects | Homeodomain Proteins - metabolism | Humans | Lung Neoplasms - metabolism | Glycoproteins - metabolism | Lung Neoplasms - pathology | Antigens, CD - metabolism | SOXB1 Transcription Factors - metabolism | Dose-Response Relationship, Drug | Flow Cytometry | Peptides - metabolism | Neoplastic Stem Cells - metabolism | Hyaluronan Receptors - metabolism | Biomarkers, Tumor - metabolism | Antineoplastic Agents - pharmacology | Aldehyde Dehydrogenase - metabolism | Carcinoma, Non-Small-Cell Lung - pathology | Cell Survival - drug effects | Nanog Homeobox Protein | Carcinoma, Non-Small-Cell Lung - metabolism | Cisplatin - pharmacology | AC133 Antigen | beta Catenin - metabolism | Octamer Transcription Factor-3 - metabolism | Cell Line, Tumor | Cell Proliferation - drug effects | Cell Cycle - drug effects | Drug Resistance, Neoplasm - drug effects | Proteins | Cell death | Analysis | Stem cells | Lung cancer, Small cell | Lung cancer, Non-small cell | Cisplatin | Cell proliferation | Health sciences | Biotechnology | Flow cytometry | Dehydrogenases | Oct-4 protein | Lung cancer | DNA damage | Oncology | Cancer therapies | β-catenin | Signal transduction | Platinum | CD44 antigen | Deoxyribonucleic acid | Cell cycle | G1 phase | Medical research | Subpopulations | Damage assessment | Cell survival | Markers | Non-small cell lung carcinoma | Tumor cell lines | Survival | Medicine | Hospitals | Molecular modelling | Cell lines | Sensitivity enhancement | DNA adducts | Pluripotency | Tumors | Apoptosis | Cancer
Journal Article
Brain Behavior and Immunity, ISSN 0889-1591, 02/2018, Volume 68, pp. 132 - 145
Journal Article
British Journal of Pharmacology, ISSN 0007-1188, 02/2010, Volume 159, Issue 4, pp. 898 - 908
Background:  Solute carriers (SLCs), in particular organic cation transporters (OCTs), have been implicated in the cellular uptake of platinum-containing... 
platinum uptake | SLC22A2 | oxaliplatin | solute carrier (SLC) | organic cation transporter (OCT) | drug resistance | cisplatin | Antineoplastic Agents/metabolism/pharmacology/therapeutic use | Cell Line | Carboplatin/metabolism | Organoplatinum Compounds/metabolism/pharmacology/therapeutic use | Platinum Compounds/metabolism/pharmacology/therapeutic use | Humans | Drug Resistance, Neoplasm | Treatment Outcome | Cell Survival/drug effects | Organic Cation Transport Proteins/antagonists & inhibitors/genetics/metabolism | Ovarian Neoplasms/drug therapy/genetics/metabolism | RNA, Messenger/metabolism | Dose-Response Relationship, Drug | Spectrophotometry, Atomic | Cisplatin/metabolism | Transfection | Biological Transport | Cell Line, Tumor | Female | Kinetics | Solute carrier (SLC) | Organic cation transporter (OCT) | Oxaliplatin | Drug resistance | Cisplatin | Platinum uptake | MEMBRANE TRANSPORTERS | COPPER TRANSPORTERS | OVARIAN-CANCER | CELL-LINES | CISPLATIN-INDUCED APOPTOSIS | PHARMACOLOGY | RESISTANCE | PHARMACOLOGY & PHARMACY | CLINICAL ACTIVITY | EXPRESSION | Antineoplastic Agents - therapeutic use | RNA, Messenger - metabolism | Organic Cation Transporter 2 | Organoplatinum Compounds - pharmacology | Antineoplastic Agents - metabolism | Ovarian Neoplasms - genetics | Platinum Compounds - therapeutic use | Organic Cation Transport Proteins - antagonists & inhibitors | Organoplatinum Compounds - metabolism | Antineoplastic Agents - pharmacology | Ovarian Neoplasms - metabolism | Ovarian Neoplasms - drug therapy | Cell Survival - drug effects | Organic Cation Transport Proteins - metabolism | Cisplatin - metabolism | Carboplatin - metabolism | Organic Cation Transport Proteins - genetics | Organoplatinum Compounds - therapeutic use | Platinum Compounds - pharmacology | Platinum Compounds - metabolism | Index Medicus | Research Papers
Journal Article
British Journal of Cancer, ISSN 0007-0920, 01/2016, Volume 114, Issue 2, pp. 177 - 187
Background: Oestrogen receptor-negative (ER-) breast cancer is intrinsically sensitive to chemotherapy. However, tumour response is often incomplete, and... 
CELLS | REDUCES TUMOR-GROWTH | STAT1 | DNA-DAMAGE | chemotherapy | IFN | THERAPY | NEOADJUVANT CHEMOTHERAPY | ONCOLOGY | ER-negative breast cancer | GENE-EXPRESSION | RESISTANCE | PATHWAY ANALYSIS | predictive signature | XENOGRAFTS | Caspase 7 - metabolism | Immunohistochemistry | Receptors, Estrogen - metabolism | Cytoskeletal Proteins - genetics | Humans | Intracellular Signaling Peptides and Proteins - drug effects | Caspase 3 - metabolism | Gene Expression Profiling | Intracellular Signaling Peptides and Proteins - metabolism | Interferon-gamma - metabolism | Carrier Proteins - drug effects | Mitochondrial Proteins - drug effects | STAT1 Transcription Factor - metabolism | Mitochondrial Proteins - metabolism | Caspase 3 - genetics | Interferon-beta - genetics | Cytokines - genetics | Intracellular Signaling Peptides and Proteins - genetics | Real-Time Polymerase Chain Reaction | Ubiquitins - metabolism | Caspase 7 - drug effects | Antigens - drug effects | Caspase 7 - genetics | Membrane Proteins - genetics | Myxovirus Resistance Proteins - drug effects | Capecitabine - pharmacology | STAT1 Transcription Factor - genetics | Breast Neoplasms - drug therapy | Blotting, Western | Breast Neoplasms - genetics | Interferon-beta - metabolism | Signal Transduction - drug effects | Mice, Nude | Membrane Proteins - drug effects | Mice | Myxovirus Resistance Proteins - genetics | Ubiquitins - drug effects | Antigens - genetics | Neoplasm Transplantation | Phosphorylation | Ubiquitins - genetics | Gene Expression Regulation, Neoplastic | Interferon-gamma - drug effects | STAT1 Transcription Factor - drug effects | Mitochondrial Proteins - genetics | Interferon-beta - drug effects | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Breast Neoplasms - metabolism | In Situ Hybridization | Caspase 3 - drug effects | Cytoskeletal Proteins - metabolism | Female | Cytoskeletal Proteins - drug effects | Membrane Proteins - metabolism | Interferon-gamma - genetics | Cytokines - metabolism | Antigens - metabolism | Cisplatin - pharmacology | Xenograft Model Antitumor Assays | Carrier Proteins - genetics | Animals | Carrier Proteins - metabolism | Cytokines - drug effects | Myxovirus Resistance Proteins - metabolism | Translational Therapeutics
Journal Article
Food and Chemical Toxicology, ISSN 0278-6915, 04/2015, Volume 78, pp. 17 - 25
Cisplatin is an effective chemotherapeutic agent successfully used in the treatment of a wide range of solid tumors, while its usage is limited due to its... 
Interleukin 6 | Tumor necrosis factor-α | Ginseng | Tumor suppressor P53 | DNA damage | Cisplatin | Tumor suppressor p53 | APOPTOSIS | ACTIVATION | ACID | PANAX-GINSENG | FOOD SCIENCE & TECHNOLOGY | Tumor necrosis factor-alpha | METABOLISM | ANTIOXIDANT | ENZYMES | LIVER | TOXICOLOGY | INDUCED NEPHROTOXICITY | EXTRACT | Tumor Necrosis Factor-alpha - metabolism | Up-Regulation | Kidney - pathology | Apoptosis - drug effects | Glutathione - metabolism | Tumor Necrosis Factor-alpha - genetics | Male | Urea - blood | Tumor Suppressor Protein p53 - genetics | Cisplatin - administration & dosage | Plant Preparations - pharmacology | Kidney Diseases - chemically induced | DNA Fragmentation - drug effects | Xanthine Oxidase - genetics | Interleukin-6 - metabolism | Superoxide Dismutase - metabolism | Glutathione Peroxidase - metabolism | Xanthine Oxidase - metabolism | Kidney - drug effects | Interleukin-6 - genetics | Kidney Diseases - pathology | Tumor Suppressor Protein p53 - metabolism | Adenosine Triphosphatases - metabolism | Glutathione Transferase - metabolism | Kidney Diseases - drug therapy | Rats | Thiobarbituric Acid Reactive Substances - metabolism | Kidney - cytology | Rats, Sprague-Dawley | Catalase - metabolism | Animals | Panax - chemistry | Cisplatin - adverse effects | Creatinine - blood | Adenosine Triphosphatases - genetics | Oxidative Stress - drug effects | Nitric Oxide - metabolism | Serum Albumin - metabolism | Index Medicus
Journal Article
Toxicology, ISSN 0300-483X, 2014, Volume 324, pp. 98 - 107
Highlights • Chlorogenic acid attenuated cisplatin-induced renal oxidative stress by reducing the expression of 4-HNE, HO-1 and CYP2E1. • The inhibition of... 
Emergency | Oxidative stress | Inflammatory response | Chlorogenic acid | Autophagy | Cisplatin nephrotoxicity | Apoptosis | CYCLIN D1 | INHIBITION | INDUCED OXIDATIVE STRESS | STEM-CELLS PROTECT | DNA | PHARMACOLOGY & PHARMACY | MICE | TOXICOLOGY | INDUCED NEPHROTOXICITY | RENAL INJURY | Tumor Necrosis Factor-alpha - metabolism | Cyclin D1 - metabolism | Heme Oxygenase-1 - metabolism | Kidney - pathology | Apoptosis - drug effects | Chlorogenic Acid - pharmacology | Microtubule-Associated Proteins - metabolism | Blood Urea Nitrogen | Caspase 3 - metabolism | Male | Cytochrome P-450 CYP2E1 - metabolism | Aldehydes - metabolism | Organic Cation Transporter 2 | Autophagy - drug effects | Dose-Response Relationship, Drug | Kidney - metabolism | Time Factors | Protective Agents - pharmacology | Inflammation Mediators - metabolism | Acute Kidney Injury - chemically induced | Membrane Proteins - metabolism | Organic Cation Transport Proteins - blood | Cytoprotection | Disease Models, Animal | Kidney - drug effects | Acute Kidney Injury - pathology | Acute Kidney Injury - blood | Tumor Suppressor Protein p53 - metabolism | bcl-2-Associated X Protein - metabolism | Biomarkers - blood | Acute Kidney Injury - prevention & control | Cisplatin | Regeneration - drug effects | Animals | Cyclooxygenase 2 - metabolism | Mice | Mice, Inbred BALB C | Oxidative Stress - drug effects | Proliferating Cell Nuclear Antigen - metabolism | Multidrug Resistance-Associated Proteins - metabolism | Antimitotic agents | Tumor proteins | Antineoplastic agents | Cytochrome P-450 | Index Medicus | Proteins | Stresses | Kidneys | Inhibition | Injuries
Journal Article
Cancer Letters, ISSN 0304-3835, 2010, Volume 295, Issue 1, pp. 110 - 123
Abstract It has been shown that IL-6 is elevated in the serum and ascites of ovarian cancer patients, and increased IL-6 concentration correlates with poor... 
Hematology, Oncology and Palliative Medicine | Interleukin-6 (IL-6) | Multidrug resistance-related genes | Apoptosis inhibitory proteins | Chemoresistance | Ovarian cancer | CARCINOMA-CELLS | X-LINKED INHIBITOR | DRUG-RESISTANCE | APOPTOSIS PROTEIN | IN-VITRO | INCREASES EFFICACY | ONCOLOGY | GENE-EXPRESSION | REGULATED PROTEIN-KINASE | MULTIDRUG-RESISTANCE | UP-REGULATION | Paclitaxel - pharmacology | Humans | ATP-Binding Cassette, Sub-Family B, Member 1 - metabolism | Gene Expression Regulation, Neoplastic | bcl-X Protein - genetics | ras Proteins - metabolism | Drug Resistance, Neoplasm | Phosphatidylinositol 3-Kinases - metabolism | raf Kinases - metabolism | Proto-Oncogene Proteins c-bcl-2 - metabolism | Female | Antineoplastic Agents - pharmacology | Ovarian Neoplasms - metabolism | Proto-Oncogene Proteins c-akt - metabolism | Interleukin-6 - metabolism | Ovarian Neoplasms - drug therapy | Glutathione S-Transferase pi - genetics | Glutathione S-Transferase pi - metabolism | Cytokine Receptor gp130 - metabolism | Cisplatin - pharmacology | X-Linked Inhibitor of Apoptosis Protein - genetics | Interleukin-6 - pharmacology | Signal Transduction - drug effects | ATP-Binding Cassette, Sub-Family B, Member 1 - genetics | X-Linked Inhibitor of Apoptosis Protein - metabolism | Cell Line, Tumor | ATP Binding Cassette Transporter, Sub-Family B | bcl-X Protein - metabolism | Proto-Oncogene Proteins c-bcl-2 - genetics | Mitogen-Activated Protein Kinases - metabolism | Receptors, Interleukin-6 - metabolism | Medical research | Chemotherapy | Kinases
Journal Article
Biomedicine & Pharmacotherapy, ISSN 0753-3322, 06/2018, Volume 102, pp. 517 - 530
Cisplatin (CP) is a widely used chemotherapeutic drug, effective against a variety of solid tumours, though its utility is limited due to its multiple organ... 
Ovarian toxicity | Inflammation | Uterine toxicity | Cisplatin | Zingerone | Apoptosis | MEDICINE, RESEARCH & EXPERIMENTAL | CANCER CELLS | CYCLOPHOSPHAMIDE | NECROSIS-FACTOR-ALPHA | DAMAGE | FERTILITY | ANTIOXIDANT | PHARMACOLOGY & PHARMACY | GROWTH-FACTOR | ZINGIBER-OFFICINALE | NF-KAPPA-B | INDUCED HEPATOTOXICITY | Estradiol - blood | Tumor Necrosis Factor-alpha - metabolism | Uterus - pathology | Inflammation - pathology | Rats, Wistar | Apoptosis - drug effects | Glutathione - metabolism | Antioxidants - metabolism | Uterus - drug effects | Caspase 3 - metabolism | Guaiacol - pharmacology | NF-kappa B - metabolism | Interleukin-1beta - metabolism | Guaiacol - analogs & derivatives | Follicle Stimulating Hormone - blood | Female | Ovary - drug effects | Interleukin-6 - metabolism | Deoxyguanosine - analogs & derivatives | Superoxide Dismutase - metabolism | Malondialdehyde - metabolism | Glutathione Peroxidase - metabolism | Gonadal Steroid Hormones - metabolism | Ovary - pathology | Catalase - metabolism | Animals | Ovary - enzymology | Cyclooxygenase 2 - metabolism | Cisplatin - adverse effects | Deoxyguanosine - metabolism | Uterus - enzymology | Oxidative Stress - drug effects | Oxidative stress | Cysteine | Follicle-stimulating hormone | Antineoplastic agents | Estradiol | Antimitotic agents | Antioxidants | Chemotherapy | Interleukins | Proteases | Cancer | Index Medicus
Journal Article
Journal of Controlled Release, ISSN 0168-3659, 12/2015, Volume 220, Issue Pt A, pp. 529 - 544
Hypoxia is a characteristic of cancer and plays a key role in tumorigenesis, angiogenesis and resistance to cancer therapies. SiRNA treatment is effective... 
siRNA delivery | Hypoxia | Quantum dots | pH-responsive | SYSTEMIC DELIVERY | DESIGN | BIODISTRIBUTION | CHEMISTRY, MULTIDISCIPLINARY | CO-DELIVERY | IN-VITRO | METABOLISM | CISPLATIN | RESISTANCE | PHARMACOLOGY & PHARMACY | HUMAN HEAD | EXPRESSION | RNA, Small Interfering - genetics | Deoxyglucose - metabolism | Humans | Gene Expression Regulation, Neoplastic | Tumor Microenvironment | Glucose Transporter Type 1 - metabolism | RNAi Therapeutics - adverse effects | Liver Neoplasms - therapy | Gene Transfer Techniques - adverse effects | Oxygen - metabolism | Thioctic Acid - metabolism | Cell Hypoxia | RNA, Small Interfering - chemistry | Peptides - metabolism | MCF-7 Cells | Time Factors | Cadmium Compounds - toxicity | Hypoxia-Inducible Factor 1, alpha Subunit - metabolism | Liver Neoplasms - pathology | Lysine - metabolism | Tellurium - toxicity | Polyethylene Glycols - metabolism | Cadmium Compounds - chemistry | Liver Neoplasms - genetics | Cell Survival | Hypoxia-Inducible Factor 1, alpha Subunit - genetics | Tellurium - chemistry | Tellurium - metabolism | Tumor Burden | Hydrazones - metabolism | RNAi Therapeutics - methods | Hep G2 Cells | Xenograft Model Antitumor Assays | Animals | Quantum Dots | Mice, Nude | Liver Neoplasms - metabolism | Mice, Inbred BALB C | Cadmium Compounds - metabolism | Hydrogen-Ion Concentration | RNA, Small Interfering - metabolism | Nuclear magnetic resonance spectroscopy | Genetic engineering | Hydrogen-ion concentration | Mass spectrometry | Polyols | Tumors | Drugstores | Liquid chromatography | Sulfates | Surface active agents | Lysine | Polyethylene glycol | Pharmacy | Cancer | Index Medicus
Journal Article